Skip to content

KAIROS PHARMA, LTD.

KAPA

CIK 0001962011

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$5.74M
−109.3% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.31
−30.4% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$3.68M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
21.41M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings